R&D expense · 2018–2025
Aurinia Pharmaceuticals R&D expense
$32.5M+56.4% · FY2025
Aurinia Pharmaceuticals (AUPH) reported $32.5M in R&D expense for fiscal 2025, +56.4% year on year.
| Fiscal year | R&D expense | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | $32.5M | +56.4% | Open → |
| FY20242024-12-31 | $20.8M | −58.1% | Open → |
| FY20232023-12-31 | $49.6M | +10.3% | Open → |
| FY20222022-12-31 | $45.0M | −12.0% | Open → |
| FY20212021-12-31 | $51.1M | +1.6% | Open → |
| FY20202020-12-31 | $50.3M | −4.8% | Open → |
| FY20192019-12-31 | $52.9M | +27.8% | Open → |
| FY20182018-12-31 | $41.4M | — | Open → |
R&D expense — Research and development expense is what the company charged to R&D in the income statement for the year. Most companies report no R&D at all — the line is absent rather than zero — so this ranking covers the roughly 40% of filers that do.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2018–2025 compound annual growth −3.4%
R&D expense at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Aurinia Pharmaceuticals R&D expense |url=https://companiesranked.com/en/company/aurinia-pharmaceuticals/research-and-development-expense |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Aurinia Pharmaceuticals R&D expense. CompaniesRanked. https://companiesranked.com/en/company/aurinia-pharmaceuticals/research-and-development-expenseBibTeX
@misc{companiesranked-en-company-aurinia-pharmaceuticals-research-and-development-expense-2026,
author = {{CompaniesRanked}},
title = {{Aurinia Pharmaceuticals R\&D expense}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/aurinia-pharmaceuticals/research-and-development-expense}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001600620-26-000017 · February 26, 2026
{{cite web |title=Aurinia Pharmaceuticals R&D expense — 10-K (0001600620-26-000017) |url=https://www.sec.gov/Archives/edgar/data/1600620/000160062026000017/auph-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.